Ascendis Pharma A/S (NASDAQ:ASND) Stock Has Consensus Target Price of $310.75

Ascendis Pharma A/S (NASDAQ:ASND) has been assigned a consensus rating of “Buy” from the twenty-one analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, nineteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $310.75.

A number of research analysts have weighed in on ASND shares. BMO Capital Markets reiterated an “outperform” rating on shares of Ascendis Pharma A/S in a research report on Thursday, September 10th. Morgan Stanley dropped their target price on Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 1st. Raymond James Financial lowered Ascendis Pharma A/S from a “strong-buy” rating to an “outperform” rating and set a $287.00 price target for the company. in a research note on Tuesday, September 15th. Barclays reduced their price target on Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Finally, Wedbush reiterated an “outperform” rating and set a $327.00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, September 1st.

Insider Buying and Selling

In other news, SVP Mads Bodenhoff sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the completion of the transaction, the senior vice president directly owned 3,000 shares of the company’s stock, valued at $810,570. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Jean-Jacques Bienaimé bought 2,000 shares of Ascendis Pharma A/S stock in a transaction dated Friday, August 14th. The shares were acquired at an average cost of $246.33 per share, with a total value of $492,660.00. Following the completion of the purchase, the director owned 2,900 shares in the company, valued at approximately $714,357. This trade represents a 222.22% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 40.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors and hedge funds have recently added to or reduced their stakes in ASND. Perceptive Advisors LLC lifted its holdings in Ascendis Pharma A/S by 41.6% during the first quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after purchasing an additional 450,000 shares in the last quarter. Sei Investments Co. increased its stake in shares of Ascendis Pharma A/S by 24.8% during the first quarter. Sei Investments Co. now owns 351,146 shares of the biotechnology company’s stock worth $80,318,000 after purchasing an additional 69,673 shares in the last quarter. Fred Alger Management LLC raised its position in shares of Ascendis Pharma A/S by 106.3% during the 4th quarter. Fred Alger Management LLC now owns 352,109 shares of the biotechnology company’s stock worth $75,084,000 after purchasing an additional 181,408 shares during the last quarter. Frazier Life Sciences Management L.P. raised its position in shares of Ascendis Pharma A/S by 68.9% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company’s stock worth $60,053,000 after purchasing an additional 91,822 shares during the last quarter. Finally, Pictet Asset Management Holding SA lifted its stake in Ascendis Pharma A/S by 243.0% in the 1st quarter. Pictet Asset Management Holding SA now owns 251,833 shares of the biotechnology company’s stock valued at $56,907,000 after buying an additional 178,415 shares in the last quarter.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND opened at $227.83 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.99 and a quick ratio of 2.32. The company has a 50 day moving average price of $250.06 and a 200-day moving average price of $242.21. Ascendis Pharma A/S has a 1-year low of $186.05 and a 1-year high of $282.15. The firm has a market cap of $14.21 billion, a price-to-earnings ratio of 17.67 and a beta of 0.35.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The firm had revenue of $387.22 million for the quarter, compared to analysts’ expectations of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. Equities research analysts forecast that Ascendis Pharma A/S will post 3.55 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapies for rare diseases, particularly in endocrinology. The company uses its proprietary TransCon technology platform to design medicines intended to provide sustained release of therapeutic compounds and potentially improve treatment convenience and patient outcomes.

Ascendis Pharma’s marketed products include Skytrofa (lonapegsomatropin-tcgb), a once-weekly growth hormone treatment for children with growth hormone deficiency, and Yorvipath (palopegteriparatide), a parathyroid hormone replacement therapy for adults with hypoparathyroidism.